Muhammad Hyder Junejo

Dr. Muhammad Hyder Junejo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
SDSara Dahlen
Sara Dahlen
DCDean Connolly
Dean Connolly
IAIsra Arif
Isra Arif
MJMuhammad Hyder Junejo
Muhammad Hyder Junejo
SBSusan Bewley
Susan Bewley
Catherine MeadsCatherine Meads
Catherine Meads
Objectives To identify and critically appraise published clinical practice guidelines (CPGs) regarding healthcare of gender minority/trans people. Design Systematic review and quality appraisal using AGREE II (Appraisal of Guidelines for Research and Evaluation tool), including stakeholder domain prioritisation. Setting Six databases and six CPG websites were searched, and international key opinion leaders approached. Participants CPGs relating to adults and/or children who are gender minority/trans with no exclusions due to comorbidities, except differences in sex development. Intervention Any health-related intervention connected to the care of gender minority/trans people. Main outcome measures Number and quality of international CPGs addressing the health of gender minority/trans people, information on estimated changes in mortality or quality of life (QoL), consistency of recommended interventions across CPGs, and appraisal of key messages for patients. Results Twelve international CPGs address gender minority/trans people’s healthcare as complete (n=5), partial (n=4) or marginal (n=3) focus of guidance. The quality scores have a wide range and heterogeneity whichever AGREE II domain is prioritised. Five higher-quality CPGs focus on HIV and other blood-borne infections (overall assessment scores 69%–94%). Six lower-quality CPGs concern transition-specific interventions (overall assessment scores 11%–56%). None deal with primary care, mental health or longer-term medical issues. Sparse information on estimated changes in mortality and QoL is conflicting. Consistency between CPGs could not be examined due to unclear recommendations within the World Professional Association for Transgender Health Standards of Care Version 7 and a lack of overlap between other CPGs. None provide key messages for patients. Conclusions A paucity of high-quality guidance for gender minority/trans people exists, largely limited to HIV and transition, but not wider aspects of healthcare, mortality or QoL. Reference to AGREE II, use of systematic reviews, independent external review, stakeholder participation and patient facing material might improve future CPG quality. PROSPERO registration number CRD42019154361.

10 May 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
JLJean-Matthieu L'Orphelin
Jean-Matthieu L'Orphelin
JCJ. Cassecuel
J. Cassecuel
LKL. Kandolf
L. Kandolf
CHC. A. Harwood
C. A. Harwood
PTP. Tookey
P. Tookey
EDEuropean Association of Dermato‐Oncology
European Association of Dermato‐Oncology
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune‐related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD‐1i and 50% of CTLA4i‐treated patients. Severe cutaneous irAE do not often occur but could be life‐threatening and may persist despite treatment discontinuation.Methods: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real‐world, phase IV, post‐marketing study using a follow‐up questionnaire.Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow‐up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug‐related eruptions and pigmentary diseases.Results: Inflammatory benign dermatoses (n = 63) represented the most common group of reactions (52.5%), followed by drug‐related eruptions (n = 24, 20%), pigmentary diseases (n = 23, 19.2%) and bullous diseases (n = 10, 8.3%). Grade II (n = 41, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis‐like rash, urticarial eruption and vitiligo. Grade III (n = 18, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (n = 2, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (n = 95, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time‐to‐onset of 208 days and some late‐onset events.Conclusion: Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I–II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late‐onset cutaneous irAE are not uncommon. A dermatological follow‐up helps mitigate the risk of life‐threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.

16 November 2021 in Sexually Transmitted Infections
Verified
Journal Article
Closed access
PDF file
MJMuhammad Hyder Junejo
Muhammad Hyder Junejo
MCMark Collery
Mark Collery
GWGary Whitlock
Gary Whitlock
AMAlan McOwan
Alan McOwan
VTVictoria Tittle
Victoria Tittle
DNDiarmuid Nugent
Diarmuid Nugent
Background: Primary syphilis is characterised by the appearance of an ulcerated lesion (chancre) on the anogenital or oral mucosa from which Treponema pallidum DNA may be detectable by PCR. Serological tests for syphilis may be non-reactive in early infection, even after the appearance of a chancre. We reviewed the use of a multiplex-PCR (M-PCR) test to determine the added value of T. pallidum DNA detection in the management of individuals presenting with mucocutaneous ulceration at a sexual health service in central London.Methods: We performed a cross-sectional analysis of all individuals with detectable T. pallidum DNA from September 2019 to April 2020. Electronic patient records were reviewed and concomitant results for treponemal serology and/or rapid plasma reagin (RPR) extracted, along with demographic data, history of syphilis and indices of sexual behaviour including number of sexual partners contacted. Any subsequent treponemal serology and RPR results were also reviewed.Results: M-PCR swab specimens were performed in 450 individuals, of whom 63 (14%) had detectable T. pallidum DNA; 60 of 63 (95%) were gay or bisexual men and 11 of 63 (17%) were living with HIV. A history of treated syphilis was present in 17 of 63 (27%). Same-day treponemal serology/RPR testing was performed in 58 of 63 (92%) patients. Of the 58 who had same-day syphilis serology/RPR, 9 (16%) had their syphilis infection confirmed by treponemal DNA PCR alone. A total of 165 partners were traced as contacts of infection, of whom 25 (15%) were contacts of individuals diagnosed by M-PCR testing alone.Conclusion: In individuals with T. pallidum PCR-positive lesions, around one in six in our cohort were negative on standard diagnostic serological tests for syphilis. Treponemal DNA testing is an important addition to serological assays in individuals with mucocutaneous ulceration who are at risk of recent syphilis infection and facilitates early diagnosis and contact tracing.

8 April 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MJMuhammad Hyder Junejo
Muhammad Hyder Junejo
SKSidra Saleem Khan
Sidra Saleem Khan
ELEhsan A. Larik
Ehsan A. Larik
AAAyesha Akinkugbe
Ayesha Akinkugbe
EOEdel A. O’tOole
Edel A. O’tOole
ASAisha Sethi
Aisha Sethi

7 January 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
MMMichael J Murphy
Michael J Murphy
MJMuhammad Hyder Junejo
Muhammad Hyder Junejo
OROkeroghene Rufin
Okeroghene Rufin
JCJeffrey M Cohen
Jeffrey M Cohen
CNCaroline A Nelson
Caroline A Nelson
WDWilliam Damsky
William Damsky
Molecular profiling on biopsies from 31 patients with Grover disease (GD) shows increased expression of interleukin 13 (a T helper 2 cell cytokine) to be a hallmark of GD. In a supportive retrospective series of nine patients with treatment-refractory GD, all improved with dupilumab. This work helps establish GD as a type 2 immune disorder.

16 May 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MJMuhammad Hyder Junejo
Muhammad Hyder Junejo
EHErica Hwang
Erica Hwang
OROkeroghene Rufin
Okeroghene Rufin
BSBridget E. Shields
Bridget E. Shields
MRMisha Rosenbach
Misha Rosenbach
WDWilliam Damsky
William Damsky